EAJAIC
Eurasian Journal of Anesthesiology and Intensive Care

The Eurasian Journal of Anesthesiology and Intensive Care (EAJAIC) is an independent-unbiased, peer-reviewed, "double-blind", and open-access journal of current national and international issues and reviews for original clinical and experimental research, interesting case reports, differential diagnoses, editorial opinions, letters to the editor, and educational papers in anesthesiology, algology, and intensive care medicine.

ISSN: Active
eISSN: 3023-6738
Creative Commons CC BY-NC-ND 4.0 International License.
EndNote Style

Online Manuscript System

Index
Original Article
Perioperative SARS-CoV-2 screening and comparison of immunoglobin values, a retrospective study
Abstract
Aims: The SARS-CoV-2 pandemic has posed significant challenges to perioperative management, particularly in the context of preoperative screening and immune response evaluation. Various methods, including polymerase chain reaction (PCR) tests, immunoglobulin (Ig) level assessments, chest X-rays, and computerized tomographies, have been employed to mitigate risks. This study aims to explore the differences in immune responses, particularly Ig levels, between vaccinated and non-vaccinated individuals undergoing surgery during the pandemic.
Methods: During the study period, data from 656 patients who underwent elective or urgent surgery were collected. Among these, only 86 patients had complete and reliable data on vaccination status and immunoglobulin G (IgG) and immunoglobulin M (IgM) levels. Patients with missing or incomplete information were excluded. The final 86 patients were grouped as follows: non-vaccinated and non-infected (NVNI), non-vaccinated but previously infected (NVI), and individuals who received two doses of the Biontech mRNA vaccine (B). The study compared IgG and IgM levels among these three groups.
Results: Patients in group B were significantly older than those in groups NVNI and NVI (mean age: 43.5±13.0 years vs. 30.0±13.2 years and 38.0±18.8 years, respectively; p<0.05). Ig G levels were highest in group B (median: 4641.2 AU/ml, IQR: 13137±14502), followed by group NVI (median: 345.5 AU/ml, IQR: 3236±8082), and were lowest in group NVNI (median: 2.4 AU/ml, IQR: 4.1±5.5) (p<0.05 for all comparisons). Similarly, Ig M levels were significantly higher in group B (median: 0.38 AU/ml, IQR: 0.91±1.40) than in groups NVI (median: 0.28 AU/ml, IQR: 0.61±0.93) and NVNI (median: 0.05 AU/ml, IQR: 0.18±0.29) (p<0.05), while there was no significant difference in Ig M levels between groups NVI and NVNI (p>0.05).
Conclusion: Vaccination enhances the immune response, leading to significantly higher IgG levels compared to nonvaccinated individuals, regardless of prior infection. However, some vaccinated individuals did not achieve protective antibody levels. Further research is needed to assess the clinical implications of these findings.

Keywords : Perioperative screening, SARS-CoV-2, immunoglobulin levels, vaccination

Download Article


1. Li DD, Li QH. SARS-CoV-2: vaccines in the pandemic era.Mil Med Res. 2021;8(1):1. doi:10.1186/s40779-020-00296-y
2. Dong E, Du H, Gardner L. An interactive Web-based dashboard to track COVID-19 in real time. Lancet Infect Dis. 2020;20(5):533-534. doi:10. 1016/S1473-3099(20)30120-1
3. Johns Hopkins University, Center for Science and Systems Engineering. Coronavirus Resource Center (2021).
4. Forni G, Mantovani A; COVID-19 Commission of Accademia Nazionale dei Lincei, Rome. COVID-19 vaccines: where we stand and challenges ahead.Cell Death Differ. 2021;28(2):626-639. doi:10.1038/s41418-020-00720-9
5. Liu F, Xu A, Zhang Y, et al. Patients of COVID-19 may benefit from sustained Lopinavir-combined regimen and the increase of eosinophil may predict the outcome of COVID-19 progression. Int J Infect Dis. 2020;95:183-191. doi:10.1016/j.ijid.2020.03.013
6. Ai T, Yang Z, Hou H, et al. Correlation of chest CT and RTPCR testing in Coronavirus disease 2019 (COVID-19) in China: a report of 1014 cases. Radiology. 2020;296(2):E32-E40. doi:10.1148/radiol.2020200642
7. Caruso D, Zerunian M, Polici M, et al. Chest CT features of COVID-19 in Rome, Italy. Radiology. 2020;296(2):E79-E85. doi:10.1148/radiol. 2020201237
8. French National Authority for Health. The place of serological testing in the management strategy of COVID-19. Recommendations of the French National Authority for Health (HAS); 2020.
9. Yang ZR, Jiang YW, Li FX, et al. Efficacy of SARS-CoV-2 vaccines and the dose-response relationship with three major antibodies: a systematic review and meta-analysis of randomised controlled trials.Lancet Microbe. 2023;4(4):e236-e246. doi:10.1016/S2666-5247(22)00390-1
10. Garcı&acute;a-Montero C, Fraile-Martı&acute;nez O, Bravo C, et al. An updated review of SARS-CoV-2 vaccines and the importance of effective vaccination programs in pandemic times. Vaccines. 2021;9(5):433. doi: 10.3390/vaccines9050433
11. Ibarrondo FJ, Fulcher JA, Goodman-Meza D, et al. Rapid decay of anti-SARS-CoV-2 antibodies in persons with mild Covid-19. N Engl J Med. 2020;383(11):1085-1087. doi:10.1056/NEJMc2025179
12. Moscola J, Sembajwe G, Jarrett M, et al. Prevalence of SARS-CoV-2 antibodies in health care personnel in the New York City area. JAMA. 2020;324(9):893-895. doi:10.1001/jama.2020.14765
13. Boonyaratanakornkit J, Morishima C, Selke S, et al. Clinical, laboratory, and temporal predictors of neutralizing antibodies against SARS-Cov-2 among COVID-19 convalescent plasma donor candidates. J Clin Invest. 2021;131(3):e144930. doi:10.1172/JCI144930
14. Shekerdemian LS, Mahmood NR, Wolfe KK, et al. Characteristics and outcomes of children with coronavirus disease 2019 (COVID-19) infection admitted to US and Canadian pediatric intensive care units. JAMA Pediatr. 2020;174(9):868-873. doi:10.1001/jamapediatrics.2020. 1948
15. Doria-Rose N, Suthar MS, Makowski M, et al. Antibody persistence through 6 months after the second dose of mRNA-1273 vaccine for Covid-19. N Engl J Med. 2021;384(23):2259-2261. doi:10.1056/NEJMc 2103916
16. Bwire GM. Coronavirus: why men are more vulnerable to COVID-19 than women? SN Compr Clin Med. 2020;2(7):874-876. doi:10.1007/s42399-020-00341-w
17. Vicenti I, Basso M, Gatti F, et al. Faster decay of neutralizing antibodies in never infected than previously infected healthcare workers three months after the second BNT162b2 mRNA COVID-19 vaccine dose. Int J Infect Dis. 2021;112:40-44. doi:10.1016/j.ijid.2021.08.052
18. Duro M, Duro I, Rebelo I, et al. Pre-vaccination immune response to COVID-19 in a population in Northeast Portugal.Ir J Med Sci. 2022; 191(5):1951-1958. doi:10.1007/s11845-021-02799-6
19. Choe PG, Kang CK, Suh HJ, et al. Waning Antibody Responses in Asymptomatic and Symptomatic SARS-CoV-2 Infection.Emerg Infect Dis. 2021;27(1):327-329. doi:10.3201/eid2701.203515
20. Abu Jabal K, Ben-Amram H, Beiruti K, et al. Impact of age, ethnicity, sex and prior infection status on immunogenicity following a single dose of the BNT162b2 mRNA COVID-19 vaccine: real-world evidence from healthcare workers, Israel, December 2020 to January 2021. Euro Surveill. 2021;26(6):2100096. doi:10.2807/1560-7917.ES.2021.26.6.2100096
21. Angyal A, Longet S, Moore SC, et al. T-cell and antibody responses to first BNT162b2 vaccine dose in previously infected and SARS-CoV-2-naive UK health-care workers: a multicentre prospective cohort study.Lancet Microbe. 2022;3(1):e21-e31. doi:10.1016/S2666-5247(21) 00275-5
22. De Giorgi V, West KA, Henning AN, et al. Naturally acquired SARS-Cov-2 immunity persists for up to 11 months following infection. J Infect Dis. 2021;224(8):1294-1304. doi:10.1093/infdis/jiab295
23. Robbiani DF, Gaebler C, Muecksch F, et al. Convergent antibody responses to SARS-Cov-2 in convalescent individuals. Nature. 2020; 584(7821):437-442. doi:10.1038/s41586-020-2456-9
24. Liu X, Wang J, Xu X. Patterns of IgG and IgM antibody response in COVID-19 patients. Emerg Microbes Infect. 2020;9(1):1269-1274. doi:10. 1080/22221751.2020.1773324
25. Li K, Huang B, Wu M, et al. Dynamic changes in anti-SARS-CoV-2 antibodies during SARS-CoV-2 infection and recovery from COVID-19. Nat Commun. 2020;11(1):6044. doi:10.1038/s41467-020-19943-y
26. Naaber P, Tserel L, Kangro K, et al. Dynamics of antibody response to BNT162b2 vaccine after six months: a longitudinal prospective study. Lancet Reg Health Eur. 2021;10:100208. doi:10.1016/j.lanepe.2021.100208
27. Wei J, Stoesser N, Matthews PC, et al. Antibody responses to SARS-CoV-2 vaccines in 45,965 adults from the general population of the United Kingdom. Nat Microbiol. 2021;6(9):1140-1149. doi:10.1038/s41564-021-00947-3
Article available in :
Volume 2, Issue 2, 2025
Page : 61-66
https://doi.org/10.51271/EAJAIC-0031
Article Information
Received : 15 Oca 2025
Accepted : 11 Nis 2025
Published : 07 May 2025
Corresponding Author :

Halil Buluç: Department of Anesthesiology and Reanimation, Faculty of Medicine, Acıbadem University, İstanbul, Turkiye

[email protected]
Citation : Buluç H, Kara B, Acar F. Perioperative SARS-CoV-2 screening and comparison of immunoglobin values: a retrospective study. Eur J Anesthesiol Intens Care. 2025;2(2):61-66.

Read: 86
Download : 811
Cited: 0
_Footer